David Rodriguez-Luna1, Pilar Coscojuela2, Marta Rubiera2, Michael D Hill2, Dar Dowlatshahi2, Richard I Aviv2, Yolanda Silva2, Imanuel Dzialowski2, Cheemun Lum2, Anna Czlonkowska2, Jean-Martin Boulanger2, Carlos S Kase2, Gord Gubitz2, Rohit Bhatia2, Vasantha Padma2, Jayanta Roy2, Alejandro Tomasello2, Andrew M Demchuk2, Carlos A Molina2. 1. From the Stroke Unit, Departments of Neurology (D.R.-L., M.R., C.A.M.) and Neuroradiology (P.C., A.T.), Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Barcelona, Spain; Calgary Stroke Program (M.D.H., A.M.D.), Department of Clinical Neurosciences, Department of Radiology, Hotchkiss Brain Institute, University of Calgary; Department of Medicine, Neurology (D.D.), and Department of Diagnostic Imaging, Neuroradiology Section (C.L.), The Ottawa Hospital, University of Ottawa, Ottawa Hospital Research Institute; Division of Neuroradiology and Department of Medical Imaging (R.I.A.), Sunnybrook Health Sciences Centre, University of Toronto, Canada; Department of Neurology (Y.S.), Dr Josep Trueta University Hospital, Institut d'Investigació Biomèdica Girona Foundation, Spain; Department of Neurology (I.D.), University of Dresden, Germany; 2nd Department of Neurology (A.C.), Institute of Psychiatry and Neurology of Warsaw, Poland; Charles LeMoyne Hospital (J.-M.B.), University of Sherbrooke, Montreal, Canada; Department of Neurology (C.S.K.), Boston Medical Center, MA; Department of Neurology (G.G.), Dalhousie University, Halifax, Canada; Department of Neurology (R.B., V.P.), All India Institute of Medical Sciences, New Delhi; and AMRI Hospital Kolkata (J.R.), India. rodriguezluna@vhebron.net. 2. From the Stroke Unit, Departments of Neurology (D.R.-L., M.R., C.A.M.) and Neuroradiology (P.C., A.T.), Vall d'Hebron University Hospital and Vall d'Hebron Research Institute, Barcelona, Spain; Calgary Stroke Program (M.D.H., A.M.D.), Department of Clinical Neurosciences, Department of Radiology, Hotchkiss Brain Institute, University of Calgary; Department of Medicine, Neurology (D.D.), and Department of Diagnostic Imaging, Neuroradiology Section (C.L.), The Ottawa Hospital, University of Ottawa, Ottawa Hospital Research Institute; Division of Neuroradiology and Department of Medical Imaging (R.I.A.), Sunnybrook Health Sciences Centre, University of Toronto, Canada; Department of Neurology (Y.S.), Dr Josep Trueta University Hospital, Institut d'Investigació Biomèdica Girona Foundation, Spain; Department of Neurology (I.D.), University of Dresden, Germany; 2nd Department of Neurology (A.C.), Institute of Psychiatry and Neurology of Warsaw, Poland; Charles LeMoyne Hospital (J.-M.B.), University of Sherbrooke, Montreal, Canada; Department of Neurology (C.S.K.), Boston Medical Center, MA; Department of Neurology (G.G.), Dalhousie University, Halifax, Canada; Department of Neurology (R.B., V.P.), All India Institute of Medical Sciences, New Delhi; and AMRI Hospital Kolkata (J.R.), India.
Abstract
OBJECTIVE: To determine the association of ultraearly hematoma growth (uHG) with the CT angiography (CTA) spot sign, hematoma expansion, and clinical outcomes in patients with acute intracerebral hemorrhage (ICH). METHODS: We analyzed data from 231 patients enrolled in the multicenter Predicting Haematoma Growth and Outcome in Intracerebral Haemorrhage Using Contrast Bolus CT study. uHG was defined as baseline ICH volume/onset-to-CT time (mL/h). The spot sign was used as marker of active hemorrhage. Outcome parameters included significant hematoma expansion (>33% or >6 mL, primary outcome), rate of hematoma expansion, early neurologic deterioration, 90-day mortality, and poor outcome. RESULTS: uHG was higher in spot sign patients (p < 0.001) and in patients scanned earlier (p < 0.001). Both uHG >4.7 mL/h (p = 0.002) and the CTA spot sign (p = 0.030) showed effects on rate of hematoma expansion but not its interaction (2-way analysis of variance, p = 0.477). uHG >4.7 mL/h improved the sensitivity of the spot sign in the prediction of significant hematoma expansion (73.9% vs 46.4%), early neurologic deterioration (67.6% vs 35.3%), 90-day mortality (81.6% vs 44.9%), and poor outcome (72.8% vs 29.8%), respectively. uHG was independently related to significant hematoma expansion (odds ratio 1.06, 95% confidence interval 1.03-1.10) and clinical outcomes. CONCLUSIONS: uHG is a useful predictor of hematoma expansion and poor clinical outcomes in patients with acute ICH. The combination of high uHG and the spot sign is associated with a higher rate of hematoma expansion, highlighting the need for very fast treatment in ICH patients.
OBJECTIVE: To determine the association of ultraearly hematoma growth (uHG) with the CT angiography (CTA) spot sign, hematoma expansion, and clinical outcomes in patients with acute intracerebral hemorrhage (ICH). METHODS: We analyzed data from 231 patients enrolled in the multicenter Predicting Haematoma Growth and Outcome in Intracerebral Haemorrhage Using Contrast Bolus CT study. uHG was defined as baseline ICH volume/onset-to-CT time (mL/h). The spot sign was used as marker of active hemorrhage. Outcome parameters included significant hematoma expansion (>33% or >6 mL, primary outcome), rate of hematoma expansion, early neurologic deterioration, 90-day mortality, and poor outcome. RESULTS: uHG was higher in spot sign patients (p < 0.001) and in patients scanned earlier (p < 0.001). Both uHG >4.7 mL/h (p = 0.002) and the CTA spot sign (p = 0.030) showed effects on rate of hematoma expansion but not its interaction (2-way analysis of variance, p = 0.477). uHG >4.7 mL/h improved the sensitivity of the spot sign in the prediction of significant hematoma expansion (73.9% vs 46.4%), early neurologic deterioration (67.6% vs 35.3%), 90-day mortality (81.6% vs 44.9%), and poor outcome (72.8% vs 29.8%), respectively. uHG was independently related to significant hematoma expansion (odds ratio 1.06, 95% confidence interval 1.03-1.10) and clinical outcomes. CONCLUSIONS: uHG is a useful predictor of hematoma expansion and poor clinical outcomes in patients with acute ICH. The combination of high uHG and the spot sign is associated with a higher rate of hematoma expansion, highlighting the need for very fast treatment in ICHpatients.
Authors: Dar Dowlatshahi; Jason K Wasserman; Franco Momoli; William Petrcich; Grant Stotts; Matthew Hogan; Mukul Sharma; Richard I Aviv; Andrew M Demchuk; Santanu Chakraborty Journal: Stroke Date: 2013-10-31 Impact factor: 7.914
Authors: H Bart Brouwers; Guido J Falcone; Kristen A McNamara; Alison M Ayres; Alexandra Oleinik; Kristin Schwab; Javier M Romero; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Joshua N Goldstein Journal: Neurocrit Care Date: 2012-12 Impact factor: 3.210
Authors: Shoichiro Sato; Hisatomi Arima; Yoichiro Hirakawa; Emma Heeley; Candice Delcourt; Ronny Beer; Yuechun Li; Jingfen Zhang; Eric Jüettler; Jiguang Wang; Pablo M Lavados; Thompson Robinson; Richard I Lindley; John Chalmers; Craig S Anderson Journal: Neurology Date: 2014-11-05 Impact factor: 9.910
Authors: Ryan Wada; Richard I Aviv; Allan J Fox; Demetrios J Sahlas; David J Gladstone; George Tomlinson; Sean P Symons Journal: Stroke Date: 2007-02-22 Impact factor: 7.914
Authors: D Rodriguez-Luna; M Rubiera; M Ribo; P Coscojuela; S Piñeiro; J Pagola; M Hernandez-Guillamon; B Ibarra; F Romero; J Alvarez-Sabin; J Montaner; C A Molina Journal: Neurology Date: 2011-10-12 Impact factor: 9.910
Authors: Atte Meretoja; Leonid Churilov; Bruce C V Campbell; Richard I Aviv; Nawaf Yassi; Christen Barras; Peter Mitchell; Bernard Yan; Harshal Nandurkar; Christopher Bladin; Tissa Wijeratne; Neil J Spratt; Jim Jannes; Jonathan Sturm; Jayantha Rupasinghe; Jorge Zavala; Andrew Lee; Timothy Kleinig; Romesh Markus; Candice Delcourt; Neil Mahant; Mark W Parsons; Christopher Levi; Craig S Anderson; Geoffrey A Donnan; Stephen M Davis Journal: Int J Stroke Date: 2013-08-26 Impact factor: 5.266
Authors: Craig S Anderson; Yining Huang; Ji Guang Wang; Hisatomi Arima; Bruce Neal; Bin Peng; Emma Heeley; Christian Skulina; Mark W Parsons; Jong Sung Kim; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Stephane Heritier; Lewis B Morgenstern; John Chalmers Journal: Lancet Neurol Date: 2008-04-07 Impact factor: 44.182
Authors: Viesha A Ciura; H Bart Brouwers; Raffaella Pizzolato; Claudia J Ortiz; Jonathan Rosand; Joshua N Goldstein; Steven M Greenberg; Stuart R Pomerantz; R Gilberto Gonzalez; Javier M Romero Journal: Stroke Date: 2014-10-09 Impact factor: 7.914
Authors: D Michalski; C Jungk; T Brenner; M Dietrich; C Nusshag; M A Weigand; C J Reuß; C Beynon; M Bernhard Journal: Anaesthesist Date: 2020-02 Impact factor: 1.041
Authors: Gregoire Boulouis; Andrea Morotti; Andreas Charidimou; Dar Dowlatshahi; Joshua N Goldstein Journal: Stroke Date: 2017-03-13 Impact factor: 7.914
Authors: Muhammad E Haque; Refaat E Gabr; Sarah D George; Xiurong Zhao; Seth B Boren; Xu Zhang; Shun-Ming Ting; Gunghua Sun; Khader M Hasan; Sean Savitz; Jaroslaw Aronowski Journal: Front Neurosci Date: 2019-08-21 Impact factor: 4.677